Gendered and heterosexual presumptive care settings are commonplace in health care and alienate sexual and gender minority (SGM) patients from receiving routine cancer screenings. Gendered references to gynecologic and breast cancers as women’s cancer, and prostate cancer as men’s cancer, is deeply rooted into the health care system. By disentangling gender from cancer and breaking down heteronormative assumptions, clinicians can provide equitable care to all patients, and critically, improve outcomes for SGM patients. National surveys and published literature show that SGM patients often delay cancer screenings and care for fear of stigma or mistreatment, which may result in later cancer diagnoses and poorer outcomes. Health care professionals who are trained in culturally relevant and humble care engage patients in discussions about the need for cancer screenings. Providing equitable care to SGM patients requires changing the practice environment, patient communications, and information gathering processes to create an inclusive, affirming, and welcoming experience for diverse genders and sexual orientations. These changes can only be effective if the entire team, clinical and non-clinical staff alike, are trained in culturally relevant and humble education as they interact and care for SGM patients.
In this CMEO BriefCase, faculty will use case-based learning to connect gendered and heterosexual presumptive care settings to health inequities and poor outcomes for SGM patients, and then, provide examples of how to create welcoming, inclusive environments and practice cultural humility with patients.
At the end of this CME/CE activity, participants should be able to identify techniques for providing culturally relevant communication regarding screening needs to SGM.
Supported by an educational grant from Merck Sharp & Dohme Corp.
Physicians, PAs, nurse practitioners, nurses and pharmacists specializing in oncology, obstetrics, gynecology, infectious disease, and/or primary care.
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Dizon reports the following financial relationships: Consultant: DSMB/IDMC activities for AstraZeneca and Clovis Oncology. Research Support: Bristol Myers Squibb (institutional support) and Pfizer Inc. Other financial or material support: Board member for the LGBTQ Cancer Network.
Dr. Quinn reports the following financial relationships: Consultant: Flo Health, Inc.
Michael Franks, APRN, AGACNP-BC, FNP-BC
Julie Strickland, PharmD (planning committee)
David Modrak, PhD (planning committee)
Thomas Mitchell (planning committee)
Kathleen Blake, PhD (planning committee)
Susan H. Yarbrough, CHCP (planning committee)
Sharon Tordoff (planning committee)
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
NOTE: Pharmacist CE Universal Activity Number, Enduring: JA0007185-0000-22-049-H04-P.